166 related articles for article (PubMed ID: 7542523)
1. Molecular approaches to AIDS vaccine development using baculovirus expression vectors.
Kang CY
Methods Mol Biol; 1995; 39():295-315. PubMed ID: 7542523
[No Abstract] [Full Text] [Related]
2. Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain.
Deml L; Kratochwil G; Osterrieder N; Knüchel R; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):10-25. PubMed ID: 9300033
[TBL] [Abstract][Full Text] [Related]
3. Expression of HIV-2 Gag and Env antigens in E. coli.
Ulrich R; Siakkou H; Krüger DH
Acta Virol; 1992 Oct; 36(5):491. PubMed ID: 1364028
[No Abstract] [Full Text] [Related]
4. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
7. Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine.
Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S73-5. PubMed ID: 7532425
[No Abstract] [Full Text] [Related]
8. Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope.
Haglund K; Forman J; Kräusslich HG; Rose JK
Virology; 2000 Mar; 268(1):112-21. PubMed ID: 10683333
[TBL] [Abstract][Full Text] [Related]
9. Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase.
Kräusslich HG; Ochsenbauer C; Traenckner AM; Mergener K; Fäcke M; Gelderblom HR; Bosch V
Virology; 1993 Feb; 192(2):605-17. PubMed ID: 8421902
[TBL] [Abstract][Full Text] [Related]
10. Mapping of the human immunodeficiency virus type 2 envelope glycoprotein CD4 binding region and fusion domain with truncated proteins expressed by recombinant vaccinia viruses.
Otteken A; Voss G; Hunsmann G
Virology; 1993 May; 194(1):37-43. PubMed ID: 8480426
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of HIV-1 proteins in Escherichia coli by a modified expression vector and their one-step purification.
Cheynet V; Verrier B; Mallet F
Protein Expr Purif; 1993 Oct; 4(5):367-72. PubMed ID: 8251747
[TBL] [Abstract][Full Text] [Related]
12. Stable expression of the transfected HIV-1 env gene in a human B cell line: characterization of gp120-expressing clones and immunobiological studies.
Ahmad A; Ladha A; Cohen EA; Menezes J
Virology; 1993 Feb; 192(2):447-57. PubMed ID: 8421893
[TBL] [Abstract][Full Text] [Related]
13. Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system.
Yamshchikov GV; Ritter GD; Vey M; Compans RW
Virology; 1995 Dec; 214(1):50-8. PubMed ID: 8525638
[TBL] [Abstract][Full Text] [Related]
14. Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2.
McGettigan JP; Koser ML; McKenna PM; Smith ME; Marvin JM; Eisenlohr LC; Dietzschold B; Schnell MJ
Virology; 2006 Jan; 344(2):363-77. PubMed ID: 16226782
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a new dot blot assay for confirmation of human immunodeficiency virus type 1 and 2 infections using recombinant p24, gp41, gp120 and gp36 antigens.
Ravanshad M; Sabahi F; Mahboudi F; Kazemnejad A
Saudi Med J; 2006 Jan; 27(1):31-6. PubMed ID: 16432590
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 primary infection in two pairs of patients: difference in variants transmitted and clinical follow-up.
Innocenti-Francillard P; Brengel-Pesce K; Morand P; Ounanian-Paraz A; Leclercq P; Gruters R; Seigneurin JM
AIDS; 1997 Mar; 11(4):539-42. PubMed ID: 9084806
[No Abstract] [Full Text] [Related]
17. Biodiversity and bioseparation of HIV-1 envelope glycoproteins.
Shao Y; Lu Y
Crit Rev Oncog; 1999; 10(1-2):1-16. PubMed ID: 10327209
[TBL] [Abstract][Full Text] [Related]
18. A simple procedure to generate chimeric Pr55gag virus-like particles expressing the principal neutralization domain of human immunodeficiency virus type 1.
Brand D; Mallet F; Truong C; Roingeard P; Goudeau A; Barin F
J Virol Methods; 1995 Feb; 51(2-3):153-68. PubMed ID: 7537750
[TBL] [Abstract][Full Text] [Related]
19. [Assay for simultaneous detection of HIV p24 antigen and anti-HIV antibody].
Xu K; Zhang Y; Wang Y; Mbawuike I
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Dec; 16(4):377-9. PubMed ID: 12665911
[TBL] [Abstract][Full Text] [Related]
20. Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines.
Hammonds J; Chen X; Zhang X; Lee F; Spearman P
Vaccine; 2007 Nov; 25(47):8036-48. PubMed ID: 17936444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
